Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Type
Public
HQ
Plan-les-Ouates, CH
Employees
21 (est)
GeNeuro has headquartered in Plan-les-Ouates, CH

GeNeuro Locations

Plan-les-Ouates, CH

GeNeuro Metrics

GeNeuro Summary

Market capitalization

€118 M

Closing share price

€7.6
GeNeuro's latest market capitalization is €118 M.

GeNeuro Market Value History

GeNeuro Company Life